ArticleMolecular medicine reports2021
miR‑486‑5p suppresses gastric cancer cell growth and migration through downregulation of fibroblast growth factor 9.
Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- miR-3662 targets CAB39L to promote proliferation and invasion in gastric cancer.Clinical and experimental medicine · 2025Article
- Influence of the lncRNA SLC9A3-AS1 on colon cancer and the biological activities of colon cancer cells.Discover oncology · 2025Article
- LINC01224 promotes the Warburg effect in gastric cancer by activating the miR-486-5p/PI3K axis.In vitro cellular & developmental biology. Animal · 2025Article
- Molecular mechanism of aerobic exercise in miRNAs and the anti-tumoral effects.Frontiers in oncology · 2025Review
- S-RBD-modified and miR-486-5p-engineered exosomes derived from mesenchymal stem cells suppress ferroptosis and alleviate radiation-induced lung injury and long-term pulmonary fibrosis.Journal of nanobiotechnology · 2024Article
- miR-486-5p predicted adverse outcomes of SCAP and regulated K. pneumonia infection via FOXO1.BMC immunology · 2024Article
- The Molecular Pathogenesis of Tumor-SuppressiveCells · 2023Article
- Krüppel-Like Factor 2 Is a Gastric Cancer Suppressor and Prognostic Biomarker.Evidence-based complementary and alternative medicine : eCAM · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non‑coding RNAs serve essential roles in regulating mRNA and protein expression and dysregulation of non‑coding RNAs participates in a variety of types of cancer. microRNAs (miRNAs/miRs), which are 21‑24 nucleotides non‑coding RNAs, have been shown to be important for the development of gastric cancer (GC). However, the role of miR‑486‑5p in GC remains to be elucidated. The present study found that miR‑486‑5p was downregulated in GC tissues. Comparing with gastric normal cells GES‑1, GC cells, including MKN‑45, AGS, HGC27 and MKN74, had reduced abundance of miR‑486‑5p transcript. CCK8 and colony formation assays demonstrated that GC cell growth and proliferation were enhanced by miR‑486‑5p inhibitors and were suppressed by miR‑486‑5p mimics. miR‑486‑5p also suppressed cell cycle process and migration and promoted apoptosis in GC cells, as verified by propidium iodide (PI) staining, Transwell assay and PI/Annexin V staining. miR‑486‑5p downregulated fibroblast growth factor 9 (FGF9) through combining to its 3'untranslated region. Overexpression of FGF9 accelerated the growth and proliferation of GC cells. The expression of miR‑486‑5p was negatively associated with FGF9 mRNA expression in GC samples. These results revealed that miR‑486‑5p was a tumor suppressor in GC. Downregulation of FGF9 contributed to the role of miR‑486‑5p in GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.